Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Neurocrine Biosciences Inc.

BMO Capital analyst Evan Seigerman maintained a Hold rating on Neurocrine today and set a price target of $147.00. The company’s shares opened toda...

BMO Capital Sticks to Their Hold Rating for Neurocrine (NBIX)

In a report released yesterday, Cory Kasimov from Evercore ISI maintained a Buy rating on Neurocrine, with a price target of $200.00. The company’s...

Evercore ISI Keeps Their Buy Rating on Neurocrine (NBIX)

Neurocrine Biosciences (($NBIX)) announced an update on their ongoing clinical study. Neurocrine Biosciences has recently completed a Phase 2 clini...

Neurocrine Biosciences Completes Phase 2 Study on NBI-1070770 for Depression

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Neurocrine, with a price target of $168.00. The company’s s...

H.C. Wainwright Keeps Their Buy Rating on Neurocrine (NBIX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cogent Biosciences (COGT – Research Report) and Neur...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Mizuho Securities analyst Uy Ear maintained a Hold rating on Neurocrine yesterday and set a price target of $146.00. The company’s shares closed ye...

Mizuho Securities Remains a Hold on Neurocrine (NBIX)

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Neurocrine, with a price target of $192.00. The company’s shares ...

Current Quarter	$1.88	Next Quarter	$1.31
Current Year	$5.18	Next Year	$6.9
QoQ Growth	-30.3%	YoY Growth	+33.2%
3Y EPS CAGR	+53.0%	Target Price	$174.46
Consensus	Buy	Upside	+23.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NBIX	$141.83	+2.05%	967.90K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NBIX	$141.83	+2.1%	967.90K
3
4
5
6

NBIX

NBIX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Neurocrine Biosciences Inc. Data in Excel

Get Neurocrine Biosciences Inc. Data in Excel